Source comparison
BPC-157 FDA 503A Removal: Comparison of Sourcing Pathways
The following table compares the three primary sourcing pathways for BPC-157 before and after the December 2022 FDA 503A removal. 503A Compounding Pharmacy Legal for patient-specific prescriptions under state pharmacy board authority Prohibited. BPC-157 remove
This comparison does not assign a generated winner or score.
- The following table compares the three primary sourcing pathways for BPC-157 before and after the December 2022 FDA 503A removal.
- 503A Compounding Pharmacy
- Legal for patient-specific prescriptions under state pharmacy board authority
- Prohibited. BPC-157 removed from permissible bulk drug substances list
- Variable (often 95–98%)
- State pharmacy boards + FDA oversight of bulk substances
- Compounded into patient-specific medications
- No longer viable for clinical or research access
- 503B Outsourcing Facility
- Not permitted. BPC-157 lacked FDA-approved NDA required for 503B compounding
- Not permitted. Same restriction applies
- N/A. Not legally compounded
- FDA registration + cGMP compliance
- Large-scale compounding for hospitals and clinics
- Never an option for BPC-157 before or after removal
- Research Peptide Supplier
- Legal for laboratory research under 'not for human consumption' labelling
- Legal. Unaffected by 503A removal
- Typically ≥98% (verified by CoA)
- Varies by supplier; no FDA pre-approval required
- In vitro research, animal models, institutional studies
- Primary legal pathway for researchers post-removal